Olav Dalgard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9321769/publications.pdf Version: 2024-02-01



ΟΙ ΑΥ ΠΑΙ CARD

#	Article	IF	CITATIONS
1	Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations. Journal of Addictive Diseases, 2023, 41, 53-63.	1.3	2
2	Neutrophil count predicts clinical outcome in hospitalized COVIDâ€19 patients: Results from the NORâ€Solidarity trial. Journal of Internal Medicine, 2022, 291, 241-243.	6.0	9
3	Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs. Liver International, 2022, 42, 1268-1277.	3.9	9
4	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases, 2021, 72, 1392-1400.	5.8	26
5	Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway. International Journal of Drug Policy, 2021, 96, 103165.	3.3	14
6	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 2021, 12, 2349.	12.8	194
7	Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. Journal of Viral Hepatitis, 2021, 28, 1177-1189.	2.0	12
8	Mortality among amphetamine users with hepatitis C virus infection: A nationwide study. PLoS ONE, 2021, 16, e0253710.	2.5	3
9	Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). PLoS Medicine, 2021, 18, e1003653.	8.4	29
10	Hepatitis C in Iceland: a milestone for global elimination. The Lancet Gastroenterology and Hepatology, 2021, 6, 599-600.	8.1	1
11	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. Annals of Internal Medicine, 2021, 174, 1261-1269.	3.9	84
12	Hepatitis C reinfection in former and active injecting drug users in Belgium. Harm Reduction Journal, 2021, 18, 102.	3.2	1
13	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. Clinical Infectious Diseases,	5.8	19
14	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Clinical Infectious Diseases, 2020, 71, e115-e124.	5.8	53
15	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 2020, 72, 643-657.	3.7	103
16	A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nature Communications, 2020, 11, 5284.	12.8	66
17	Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21,	1.6	7
18	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clinical Infectious Diseases, 2019, 69, 2218-2227.	5.8	52

OLAV DALGARD

#	Article	IF	CITATIONS
19	SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression. Journal of Hepatology, 2019, 70, e733.	3.7	5
20	Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC Infectious Diseases, 2019, 19, 943.	2.9	28
21	The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients. Scandinavian Journal of Gastroenterology, 2019, 54, 1172-1175.	1.5	1
22	Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County. BMC Infectious Diseases, 2019, 19, 955.	2.9	15
23	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver International, 2019, 39, 20-30.	3.9	88
24	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Journal of Hepatology, 2018, 68, 402-411.	3.7	105
25	EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology, 2018, 69, 461-511.	3.7	1,489
26	Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway. Pharmacoeconomics, 2018, 36, 591-601.	3.3	13
27	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 153-161.	8.1	231
28	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. The Lancet Gastroenterology and Hepatology, 2018, 3, 125-133.	8.1	128
29	Increased hope following successful treatment for hepatitis C infection. Journal of Advanced Nursing, 2018, 74, 724-733.	3.3	3
30	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. International Journal of Drug Policy, 2018, 62, 14-23.	3.3	58
31	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International Journal of Drug Policy, 2018, 62, 94-103.	3.3	22
32	Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. PLoS ONE, 2018, 13, e0190146.	2.5	9
33	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	8.1	1,619
34	Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C. Journal of Hepatology, 2017, 66, 1101-1103.	3.7	14
35	Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. Journal of Clinical Virology, 2017, 92, 32-38.	3.1	32
36	Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. International Journal of Drug Policy, 2017, 47, 177-186.	3.3	13

OLAV DALGARD

#	Article	IF	CITATIONS
37	Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International Journal of Drug Policy, 2017, 47, 230-238.	3.3	28
38	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. International Journal of Drug Policy, 2017, 47, 51-60.	3.3	54
39	Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infectious Diseases, 2017, 17, 420.	2.9	6
40	Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973–2030. BMC Infectious Diseases, 2017, 17, 541.	2.9	14
41	Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections—A Scandinavian real-life study. PLoS ONE, 2017, 12, e0179764.	2.5	28
42	Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study. PLoS ONE, 2016, 11, e0166451.	2.5	34
43	Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy. Annals of Internal Medicine, 2016, 165, 625.	3.9	322
44	Hepatitis C reinfection after sustained virological response. Journal of Hepatology, 2016, 64, 1020-1026.	3.7	122
45	HCV epidemiology in high-risk groups and the risk of reinfection. Journal of Hepatology, 2016, 65, S33-S45.	3.7	146
46	Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. Journal of Hepatology, 2016, 64, 19-28.	3.7	60
47	Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. PLoS ONE, 2016, 11, e0155142.	2.5	10
48	The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection. PLoS ONE, 2015, 10, e0120866.	2.5	2
49	Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. International Journal of Drug Policy, 2015, , 101669.	3.3	0
50	Debilitating fatigue as a treatment indication in chronic hepatitis C. Journal of Hepatology, 2015, 63, 1533-1534.	3.7	1
51	Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 2015, 26, 1028-1038.	3.3	159
52	Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study. Journal of Hepatology, 2014, 60, 260-266.	3.7	26
53	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International, 2011, 31, 30-60.	3.9	333
54	IL28Bgenetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology, 2011, 53, 746-754.	7.3	118

#	Article	IF	CITATIONS
55	In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials. European Journal of Gastroenterology and Hepatology, 2010, 22, 552-556.	1.6	10